Disease Domain | Count |
---|---|
Neoplasms | 6 |
Infectious Diseases | 5 |
Hemic and Lymphatic Diseases | 5 |
Immune System Diseases | 4 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 5 |
Bispecific T-cell Engager (BiTE) | 4 |
Monoclonal antibody | 2 |
Inactivated vaccine | 1 |
Bispecific antibody | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date15 Nov 2007 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Nov 2024 |
Sponsor / Collaborator |
Start Date15 Oct 2024 |
Sponsor / Collaborator |
Start Date25 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant Zoster vaccine (Beijing Lvzhu) | Herpes Zoster More | NDA/BLA |
Bevacizumab(Beijing Science Sun) ( VEGF-A ) | Metastatic Colorectal Carcinoma More | Phase 3 |
Enterovirus type 71 vaccine(Beijing Luzhu Biopharmaceutical) | Enterovirus 71 infection More | Phase 2 |
K193 bispecific antibody(Beijing Lüzhu Biotechnology) ( CD19 x CD3ε ) | Diffuse Large B-Cell Lymphoma More | Phase 1 |
Recombinant Varicella Vaccine (CHO cell) (Beijing Lüzhu Biotechnology) | Chickenpox More | IND Application |